T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Alibaba
BABA
$300B
| $1.13B | 0.14% |
9,979,903
-3,307,713
| -25% | -$324M |
|
152
Xcel Energy
XEL
$49.1B
| $1.13B | 0.14% |
16,005,183
-6,683,898
| -29% | -$486M |
|
153
Match Group
MTCH
$8.4B
| $1.13B | 0.14% |
16,248,442
+827,025
| +5% | +$67.1M |
|
154
Bristol-Myers Squibb
BMY
$130B
| $1.12B | 0.14% |
14,587,023
-1,216,245
| -8% | -$92.6M |
|
155
Nutrien
NTR
$32.1B
| $1.12B | 0.14% |
14,092,814
+7,949,254
| +129% | +$772M |
|
156
Trade Desk
TTD
$6.34B
| $1.09B | 0.14% |
26,139,359
+5,052,749
| +24% | +$277M |
|
157
Cooper Companies
COO
$15B
| $1.09B | 0.14% |
13,946,660
-320,832
| -2% | -$28.4M |
|
158
Broadcom
AVGO
$1.98T
| $1.08B | 0.14% |
22,293,680
-351,320
| -2% | -$19.7M |
|
159
Chevron
CVX
$386B
| $1.08B | 0.14% |
7,453,505
-4,076,073
| -35% | -$674M |
|
160
Assurant
AIZ
$13.9B
| $1.07B | 0.14% |
6,179,888
-48,594
| -0.8% | -$8.8M |
|
161
Morgan Stanley
MS
$342B
| $1.07B | 0.13% |
14,038,523
-2,615,917
| -16% | -$214M |
|
162
AvalonBay Communities
AVB
$25.7B
| $1.06B | 0.13% |
5,465,899
+1,759,576
| +47% | +$381M |
|
163
News Corp Class A
NWSA
$15.5B
| $1.06B | 0.13% |
68,042,667
+12,921,681
| +23% | +$237M |
|
164
Starbucks
SBUX
$124B
| $1.04B | 0.13% |
13,598,025
+3,133,826
| +30% | +$241M |
|
165
PepsiCo
PEP
$189B
| $1.04B | 0.13% |
6,232,728
-440,683
| -7% | -$74.2M |
|
166
Avery Dennison
AVY
$13.7B
| $1.04B | 0.13% |
6,398,230
+437,559
| +7% | +$74.8M |
|
167
Medtronic
MDT
$116B
| $1.03B | 0.13% |
11,433,785
-7,844,168
| -41% | -$795M |
|
168
Abbott
ABT
$192B
| $1.02B | 0.13% |
9,412,794
+1,074,432
| +13% | +$122M |
|
169
Western Alliance Bancorporation
WAL
$9.01B
| $1.02B | 0.13% |
14,481,293
+808,692
| +6% | +$61.9M |
|
170
Alnylam Pharmaceuticals
ALNY
$30B
| $1.02B | 0.13% |
6,997,082
+202,916
| +3% | +$28.8M |
|
171
Regeneron Pharmaceuticals
REGN
$82.2B
| $1B | 0.13% |
1,694,308
+813,967
| +92% | +$529M |
|
172
Las Vegas Sands
LVS
$29.6B
| $1B | 0.13% |
29,793,305
+440,770
| +2% | +$15.3M |
|
173
Costco
COST
$421B
| $998M | 0.13% |
2,083,092
-141,801
| -6% | -$71.9M |
|
|
DAY
174
DELISTED
Dayforce
DAY
| $991M | 0.13% |
21,041,352
-2,841,164
| -12% | -$158M |
|
175
CoStar Group
CSGP
$12.4B
| $982M | 0.12% |
16,260,766
-2,338,425
| -13% | -$142M |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.